Welcome.
Are you a healthcare professional?

This website contains promotional information for Chiesi's respiratory products, and is intended solely for UK healthcare professionals. Please confirm below, or go back to the home page.

UK-RES-2000248 Feb 2020

You are now leaving Chiesi's website

By clicking this link, you will be taken to a website that is not owned or controlled by Chiesi. Chiesi is not responsible for the content provided on that site.

Continue
Go back

UK-RES-2000003 Jan 2020

INTENDED FOR UK HEALTHCARE PROFESSIONALS
Atimos® Formoterol pMDI logo
Background
Atimos® Formoterol pMDI logo with device

Asthma: Licensed in adults and adolescents 12 years and above
COPD: Licensed in adults 18 years and above

Asthma: Licensed in adults and
adolescents 12 years and above
COPD: Licensed in adults 18 years and above

Asthma: Licensed in adults and adolescents 12 years and above
COPD: Licensed in adults 18 years and above

Why prescribe Atimos®

Prescribing Atimos for patients with asthma[[1]]

Adults and adolescents aged 12 years and above:
The usual dose is one inhalation twice daily (one in the morning and one in the evening). This equates to 24 micrograms of formoterol fumarate dihydrate per day.

In severe cases, a dose of two inhalations twice daily can be taken (two in the morning and two in the evening). This equates to 48 micrograms of formoterol fumarate dihydrate per day.

The maximum daily dose is 4 inhalations (48 micrograms of formoterol fumarate dihydrate).
Atimos® Modulite® pMDI

Although Atimos has a rapid onset of action, long-acting inhaled bronchodilators should be used for maintenance bronchodilator therapy. Atimos is not intended to relieve acute asthma attacks.

In the event of an acute attack, a short-acting β2-agonist should be used. Patients should be advised not to stop or change their steroid therapy when Atimos is introduced.

If the symptoms persist or worsen, or if the recommended dose of Atimos fails to control symptoms (maintain effective relief), this is usually an indication of a worsening of the underlying condition.

Children younger than 12 years of age:
The safety and efficacy of Atimos in children younger than 12 years of age has not been established yet, therefore Atimos should not be used in children.

Atimos® Modulite® pMDI

Prescribing Atimos for patients with chronic obstructive pulmonary disease (COPD)[[1]]

Adults (aged 18 and above):
The usual dose is one inhalation twice daily (one in the morning and one in the evening). This equates to 24 micrograms of formoterol fumarate dihydrate per day.

The daily dose for regular use should not exceed 2 inhalations. If required, additional inhalations above those prescribed for regular therapy may be used for relief of symptoms, up to a maximum total daily dose of 4 inhalations (regular plus required). More than 2 inhalations should not be taken on any single occasion.

For additional information to share with your patients who have been prescribed Atimos, please visit our Atimos patient and carer site.

Reference:
1. Atimos Summary of Product Characteristics. Chiesi Limited.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Limited on 0800 0092329 (UK) or PV.UK@Chiesi.com.